Integrating U=U Into HIV Counseling in South Africa (INTUIT-2.0)
- Sponsor
- Boston University
- Study ID
- NCT07199634
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- "Undetectable & You" HIV treatment literacy app — OTHERThe app delivers information on the transmission prevention benefits of HIV treatment through the Undetectable Equals Untransmutable (U=U) message, alongside real-life video testimonials of patients living with HIV (PLHIV) and their partners. It underscores the key behavioral skills required for U=U, namely, ART adherence and viral load monitoring.
Study Details
Undetectable = Untransmittable (U=U) is the scientific consensus that people with human immunodeficiency virus (HIV) who achieve viral suppression through antiretroviral treatment (ART) cannot transmit the virus sexually. While global studies confirm this, awareness of U=U remains very limited in sub-Saharan Africa, including South Africa, where only two-thirds of people living with HIV (PLHIV) are virally suppressed despite having the largest treatment program globally. Many PLHIV delay or avoid ART because they feel healthy and perceive little benefit, while also fearing stigma, disclosure, and social costs. U=U offers powerful motivation for ART uptake and adherence by reframing treatment as both a personal health and prevention tool, reducing internalised stigma, strengthening self-image, and supporting HIV prevention altruism. Yet, dissemination in Africa has lagged. To address this, the investigators developed an HIV treatment literacy App called "Undetectable \& You", which delivers accurate U=U information alongside real-life video testimonials of PLHIV and their partners. This research will assess the impact of the "Undetectable \& You" App in a cluster-randomized trial in South Africa. The study will establish whether disseminating U=U information via a video-based app at the time of HIV counselling improves retention in care and viral suppression among PLHIV in South Africa. Aim 1. Refine the "Undetectable \& You" App to help PLHIV navigate U=U within relationships. Aim 2. Establish the real-world impact of "Undetectable \& You" on retention on ART and viral suppression in a cluster-randomized trial.
Key Dates
- First listed
- Sep 30, 2025
- Start date
- Aug 31, 2026
- Status verified
- Jun 2026
- Primary completion
- Apr 30, 2028
- Completion
- Jan 31, 2029
Study Design
- Enrollment
- 880 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Experimental: Immediate intervention Group AParticipants whose clinic was randomized into Group A will have immediate access to the "Undetectable \& You" intervention app as part of HIV counseling.
- Active Comparator: Deferred intervention Group BParticipants whose clinic was randomized into Group B will get the intervention app at 16 months, after data collection for primary outcomes is complete.
Primary Outcome Measure
HIV viral load <200 copies/mL [ Time Frame: 3-9 months (on average 6 months) ]
Central Contacts
- Jacob Bor, ScD, SM(617) 414-1446
- Dorina Onoya, PhD, MBA
Find similar trials
Related Studies
- Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIVRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- Viral Load in Blood and Lymph Tissues in People Living With HIVRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Leukapheresis to Obtain Plasma or Lymphocytes for Studies of HIV-infected Patients, Including Long-term Non-progressorsRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland